What is Whole-cell SELEX? Whole-cell SELEX (Systematic Evolution of Ligands by EXponential enrichment) is a technique used to discover aptamers (single-stranded DNA or RNA molecules) that bind specifically to a target living cell. Unlike traditional SELEX that uses a purified protein target, whole-cell SELEX presents the target in its native, complex cellular environment. This allows for the selection of aptamers against: Native cell-surface proteins in their proper folding and post-translational modifications. Complex targets like transmembrane receptors in their natural lipid environment. Unknown surface biomarkers without prior knowledge of the cell's molecular makeup. Specific cell states (e.g., activated, cancerous, infected) based on differences in surface expression. The Core Process: How Whole-cell SELEX Works A professional service will manage this complex, iterative pipeline: Library & Design: Starting with a vast, random synthetic oligonucleotide library (10^14 - 10^15 unique sequences). Positive Selection: Incubating the library with the target cells (e.g., cancer cells, stem cells, bacteria). Aptamers that bind to any surface structure are retained. Counter-Selection (Critical Step): The bound pool is then exposed to non-target or control cells (e.g., healthy cells, a different cell line). Sequences that bind to these are discarded. This step is crucial for generating specificity. Elution & Amplification: Aptamers specifically bound to the target cells are recovered, amplified by PCR…
What is Protein SELEX? SELEX (Systematic Evolution of Ligands by EXponential Enrichment) is an iterative, in vitro process used to discover aptamers—single-stranded DNA or RNA molecules that bind to a specific target (like a protein) with high affinity and specificity. Protein SELEX specifically refers to using a purified protein as the target to isolate aptamers against it. These aptamers are often called "chemical antibodies" due to their similar binding function. Core Workflow of a Protein SELEX Service A professional service will manage this entire complex process, typically involving the following stages: 1. Project Design & Consultation Target Characterization: Discussing the target protein's properties (size, purity, stability, domains, post-translational modifications). Selection Strategy: Choosing the right SELEX variant (e.g., Nitrocellulose filter, Magnetic bead, Capillary Electrophoresis, or Cell-SELEX for membrane proteins). Defining counter-selection steps to avoid binders to unwanted tags or impurities. Library Design: Using a standard or custom random oligonucleotide library (e.g., 40-60 random nucleotides flanked by primer sites). 2. The SELEX Cycle (Repeated 8-15 Rounds) mermaid graph TD A[Start: ssDNA/RNA Library<br>~10^15 unique sequences] --> B{Incubation with<br>Target Protein}; B --> C[Partition: Separate<br>Bound from Unbound Sequences]; C --> D[Elution: Recover<br>Bound Sequences]; D --> E[Amplification:<br>PCR (DNA) or RT-PCR (RNA)]; E --> F[Purification:<br>Regenerate ssDNA/RNA for next round]; F --> G{Enrichment<br>Sufficient?}; G -- No…
Traditional SELEX (Systematic Evolution of Ligands by EXponential enrichment) is a method to select high-affinity, specific nucleic acid aptamers from a vast random library (10¹³-10¹⁵ sequences). The bottleneck has always been the final cloning and Sanger sequencing of only a few dozen candidates, which often misses rare, high-performance aptamers. NGS-assisted SELEX integrates Next-Generation Sequencing at multiple rounds of the SELEX process. This provides a massive, data-rich view of the entire evolutionary landscape, enabling intelligent selection and identification of the best aptamers. Typical Workflow of an NGS-Assisted SELEX Service A professional service provider will manage this entire pipeline: Project Design & Library Synthesis: Collaboration to define target (protein, small molecule, cell), counter-selection requirements, and library design (random region length, fixed primers for NGS). Parallel SELEX Execution: Performing the iterative selection process (binding, partitioning, amplification) across multiple rounds (usually 8-12). Key NGS Integration Points: Initial Library Analysis: Sequencing the naive library to confirm diversity and complexity. Monitoring Rounds (e.g., Rounds 3, 6, 9): Taking small samples from intermediate rounds for NGS. This is the critical advantage. It tracks: Sequence Enrichment: Which families are becoming more abundant. Diversity Collapse: When to stop selection before losing good candidates. Informed Decision-Making: Data guides adjustments in selection stringency for subsequent rounds. Final Round Deep Sequencing: Comprehensive NGS of…
What is Solution-Phase SELEX? SELEX (Systematic Evolution of Ligands by EXponential Enrichment) is the iterative process used to discover aptamers—single-stranded DNA or RNA molecules that bind to a specific target with high affinity and specificity. Solution-Phase SELEX refers to performing the selection process with the target molecule free in solution, rather than immobilized on a solid surface (like beads or a column). This often involves a partitioning step that separates bound from unbound sequences using a method like filtration, capillary electrophoresis, or magnetic bead capture of the target. Key Advantages of Solution-Phase SELEX Preservation of Native Target Conformation: The target is in its natural, free state in solution. This is crucial for complex targets like membrane proteins, which can denature or present epitopes unnaturally when immobilized. Access to All Binding Sites: All surfaces of the target are available for aptamer binding, increasing the diversity of potential aptamers discovered. Avoidance of Non-Specific Binding to Solid Support: Reduces background noise from library sequences sticking to the immobilization matrix (e.g., sepharose beads, plastic wells), leading to cleaner selections. Better for Small Molecules and Peptides: Ideal for targets that are difficult to immobilize without blocking their functional groups. Mimics Physiological Conditions: More closely replicates how the aptamer will interact with its target in real-world applications…
Aptamers are single-stranded oligonucleotides that fold into defined architectures and bind to targets such as proteins. In binding proteins they often inhibit protein–protein interactions and thereby may elicit therapeutic effects such as antagonism. Aptamers are discovered using SELEX (systematic evolution of ligands by exponential enrichment), a directed in vitro evolution technique in which large libraries of degenerate oligonucleotides are iteratively and alternately partitioned for target binding. They are then amplified enzymatically until functional sequences are identified by the sequencing of cloned individuals. For most therapeutic purposes, aptamers are truncated to reduce synthesis costs, modified at the sugars and capped at their termini to increase nuclease resistance, and conjugated to polyethylene glycol or another entity to reduce renal filtration rates. The first aptamer approved for a therapeutic application was pegaptanib sodium (Macugen; Pfizer/Eyetech), which was approved in 2004 by the US Food and Drug Administration for macular degeneration. Eight other aptamers are currently undergoing clinical evaluation for various haematology, oncology, ocular and inflammatory indications. Aptamers are ultimately chemically synthesized in a readily scalable process in which specific conjugation points are introduced with defined stereochemistry. Unlike some protein therapeutics, aptamers do not elicit antibodies, and because aptamers generally contain sugars modified at their 2′-positions,…
What is an Aptamer? An aptamer is a short, single-stranded oligonucleotide (DNA or RNA) or peptide that binds to a specific target molecule (e.g., proteins, small molecules, cells, viruses) with high affinity and specificity. Often called "chemical antibodies," they offer advantages like stability, low-cost synthesis, and minimal batch-to-batch variation. The Core Process: SELEX The standard method for aptamer selection is SELEX (Systematic Evolution of Ligands by EXponential enrichment). Basic SELEX Workflow: Library Synthesis: Create a vast random-sequence oligonucleotide library (typically 10¹³ - 10¹⁵ unique sequences) flanked by constant primer regions for PCR amplification. Incubation: The library is incubated with the target molecule under controlled conditions (buffer, temperature, time). Partitioning: Bound sequences are separated from unbound ones. This is the most critical step and varies based on target (e.g., filtration, affinity columns, magnetic bead separation). Elution: Bound aptamers are recovered from the target (e.g., by denaturation or competitive elution). Amplification: The recovered pool is amplified by PCR (for DNA) or RT-PCR (for RNA) to create an enriched library for the next round. Iteration: Steps 2-5 are repeated (typically 8-15 rounds) to progressively enrich for sequences with the highest affinity and specificity. Cloning & Sequencing: The final enriched pool is cloned and sequenced to identify individual aptamer candidates. Key Variants of…
CUSTOM APTAMER DISCOVERY & DEVELOPMENT is the process of creating target-specific single-stranded DNA or RNA aptamers—short nucleic acids that fold into 3D shapes capable of binding proteins, small molecules, cells, vesicles, or other targets with antibody-like selectivity. Most custom programs rely on SELEX (Systematic Evolution of Ligands by EXponential enrichment), then refine “hits” into robust, application-ready binders through sequencing-driven analysis and post-selection optimization. 1) What Aptamers Are (and Why They’re Used) Aptamers are typically ~15–90 nucleotides long and can be engineered to bind targets across a wide size range (from small molecules to whole cells). They’re attractive because they are chemically synthesized (batch-to-batch consistency), can be readily labeled (fluorophores, biotin, etc.), and are generally thermally stable and re-foldable—features that often simplify assay development and manufacturing. Common aptamer use cases Diagnostics & biosensors (capture probes, signal transducers, point-of-care formats) Targeted delivery & therapeutics research (cell-directed binding, payload delivery concepts) Affinity purification & analytical workflows (pull-downs, enrichment, separations) 2) The Core Workflow in Custom Aptamer Discovery A custom program is best thought of as a pipeline with four linked decisions: target format → selection strategy → analytics → optimization. Step A — Target Definition and “Bindability” Planning…
